AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Tissue Plasminogen ActivatorThrombolytic TherapyUrokinase-Type Plasminogen ActivatorPlasminogen ActivatorsPlasminogen Activator Inhibitor 1Coronary ThrombosisPlasminogenFibrinolytic AgentsStreptokinaseReceptors, Urokinase Plasminogen ActivatorZinc AcetateCoronary VesselsPlasminogen InactivatorsMyocardial InfarctionCatheterization, Swan-GanzFibrinolysisCoronary AngiographyMyocardial ReperfusionDogsPlasminogen Activator Inhibitor 2FibrinolysinBlood CoagulationCoronary Artery DiseaseCoronary CirculationAngioplasty, Balloon, CoronaryHypotensionFibrinCoronary StenosisCoronary Artery BypassStrokeTreatment OutcomeTime FactorsCoronary Diseasealpha-2-AntiplasminThrombosisRecombinant ProteinsBrain IschemiaReceptors, Cell SurfaceCoronary VasospasmVitronectinThrombectomyCerebral HemorrhageInjections, Intra-ArterialFibrinogenMechanical ThrombolysisProspective StudiesSerpin E2HeparinAcute DiseaseCoronary AneurysmCoronary Care UnitsEndothelium, VascularRisk FactorsCells, CulturedHemostasisUltrasonic TherapyInjections, IntravenousRNA, MessengerIntracranial HemorrhagesFollow-Up StudiesCoronary RestenosisPercutaneous Coronary InterventionElectrocardiographyCoronary OcclusionStentsInfusions, IntravenousSerine Proteinase InhibitorsKringlesPredictive Value of TestsInfusions, Intra-ArterialRetrospective StudiesFibrin Fibrinogen Degradation ProductsKineticsTomography, X-Ray ComputedAminocaproic AcidVascular PatencyPlatelet Aggregation InhibitorsInfarction, Middle Cerebral ArteryMolecular Sequence DataRecurrenceHemorrhageAnistreplaseDose-Response Relationship, DrugAntifibrinolytic AgentsCarotid Artery ThrombosisThrombinBiological MarkersSeverity of Illness IndexSerpinsCell LineFemoral VeinReperfusionAnticoagulantsIliac VeinIsoflurophateCatheterization, PeripheralMyocardial IschemiaProtein BindingAngina, UnstablePrognosis
AngioplastyAngiographyStreptokinaseTissueUROKINASE-TYPE PLASMINOGEN ACTIVATORIntravenousBypassArteriesMyocardialIschemicOutcomesPlasminRescue percutaneous coronary intThrombectomyIntra-arterial thrombolysisCatheter-Directed ThrombolysisFibrinolysisPercutaneous Coronary InterventionsStroke thrombolysisPlateletReperfusionCABGSTEMIThrombiRevascularizationCirculationOral anticoagulant therapyCardiacPPCIBlood vesselsThrombus burdenThrombolytic agentsClopidogrelHeparinOutcomeSystemicClotsTherapyIschaemic stroke
Angioplasty8
  • Facilitated PCI is defined as the intent to perform a PCI (either conventional balloon angioplasty or coronary stent placement) in the setting of STEMI following treatment with either a full dose or half dose of a fibrinolytic agent. (wikidoc.org)
  • Primary PCI is defined as the performance of percutaneous coronary intervention (PCI) (either conventional balloon angioplasty or coronary stent placement) in the setting of ST elevation MI (STEMI) without antecedent treatment with a fibrinolytic agent. (wikidoc.org)
  • Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical technique for treating obstructive coronary artery disease, including unstable angina, acute myocardial infarction (MI), and multivessel coronary artery disease (CAD). (medscape.com)
  • Example of an intravascular ultrasound (IVUS) image in percutaneous transluminal coronary angioplasty (PTCA). (medscape.com)
  • The outcome of the acute coronary thrombotic syndromes, which include unstable angina, acute myocardial infarction and abrupt closure following coronary angioplasty, may be significantly improved with 7E3 therapy. (ox.ac.uk)
  • Percutaneous transcatheter treatment of patients with deep venous thrombosis (DVT) consists of thrombus removal with catheter-directed thrombolysis, mechanical thrombectomy, angioplasty, and/or stenting of venous obstructions. (medscape.com)
  • Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. (baiminstitute.org)
  • She had a history of surgery for arterial septal defect closure, mitral valve angioplasty for mitral regurgitation, and coronary artery bypass graft surgery for coronary artery stenosis. (surgicalneurologyint.com)
Angiography15
Streptokinase4
Tissue10
  • During his fellowship at Johns Hopkins, he was involved with the first patient who was administered tissue plasminogen activator (t-PA) in 1984, a genetically engineered protein. (wikipedia.org)
  • Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. (google.ca)
  • If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. (lookformedical.com)
  • Animal models of the acute coronary syndromes suggest that 7E3 abolishes the in vivo formation of platelet thrombi, accelerates thrombolysis with tissue plasminogen activator, and prevents subsequent reocclusion. (ox.ac.uk)
  • In smaller hospitals, especially in rural areas, intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) remains the mainstay for AIS patients ( 3 , 4 ). (frontiersin.org)
  • Three patients received IV tissue plasminogen activator. (bmj.com)
  • Tissue plasminogen activator use: Evaluation and initial management of ischemic stroke from an Iowa hospital perspective. (dmu.edu)
  • 2 3 Performance measurement of an acute stroke service can be evaluated based on the time from patient arrival at the hospital to the time of alteplase (tissue plasminogen activator (tPA)) administration or door-to-needle time (DTN). (bmj.com)
  • Tissue Plasminogen Activator for Acute Ischemic Stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. (thesgem.com)
  • [1] It works by stimulating secondary fibrinolysis by plasmin through infusion of analogs of tissue plasminogen activator (tPA), the protein that normally activates plasmin. (wikimili.com)
UROKINASE-TYPE PLASMINOGEN ACTIVATOR1
Intravenous11
  • Does large vessel occlusion affect clinical outcome in stroke with mild neurologic deficits after intravenous thrombolysis? (nih.gov)
  • Given the uncertainty whether LVO has the same significance in mild and severe stroke, we compared functional outcomes after intravenous thrombolysis, based on severity and LVO. (nih.gov)
  • LVO is associated with worse functional outcome and mortality in severe stroke after intravenous thrombolysis. (nih.gov)
  • Intravenous thrombolysis (IVT) is a standard procedure for the treatment of patients with acute ischemic stroke (AIS). (frontiersin.org)
  • Intravenous thrombolysis or/and intraarterial thrombectomy to reopen occluded cerebral arteries is a standard treatment procedure for AIS patients. (frontiersin.org)
  • Further studies on how to improve the therapeutic efficacy of intravenous thrombolysis are always important. (frontiersin.org)
  • Early neurological deterioration (END) within the first 24 h after intravenous thrombolysis is a major problem leading to poor outcomes in AIS patients ( 5 ). (frontiersin.org)
  • Since 2007, intravenous thrombolysis has been recommended for the treatment of ischaemic stroke initially within 3 h of symptom onset, 1-6 and more recently within 4 ½ h of symptom onset. (bmj.com)
  • Mechanical thrombectomy, in addition to intravenous thrombolysis, has become standard in acute ischemic stroke treatment in patients with large-vessel occlusion in the anterior circulation. (ajnr.org)
  • Thrombolysis is usually intravenous . (wikimili.com)
  • They were trained regarding managing ischemic stroke with intravenous thrombolysis. (tsitn.org)
Bypass3
  • Coronary artery bypass grafting (CABG) is a type of surgery that improves blood flow to the heart. (cdc.gov)
  • Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months. (stanford.edu)
  • Stents were not used and so patients either got coronary artery bypass graph or simply had completion of their infarcts while physicians crossed their fingers. (thesgem.com)
Arteries3
Myocardial11
Ischemic5
  • Aspirin alone or in combination with a thienopyridine (dual antiplatelet therapy) reduces the risk of coronary ischemic events in patients with ACS. (jabfm.org)
  • 4 , 5 Nevertheless, catastrophic ischemic events still occur, especially in high-risk patients such as those who undergo percutaneous coronary intervention (PCI). (jabfm.org)
  • Several randomized, controlled trials have assessed the efficacy of the upstream administration of tirofiban (Platelet Receptor Inhibition for ischemic Syndrome Management in Patients Limited to very Unstable Signs and symptoms [PRISM-PLUS] regimen) in patients with non-ST-segment elevation acute coronary syndromes (ACS) (1,2) . (jacc.org)
  • At the same time, the use of tirofiban as an adjunctive medication in the catheterization laboratory (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis [RESTORE] regimen) for the prevention of ischemic complications during percutaneous coronary intervention (PCI) gave controversial results. (jacc.org)
  • Revascularization for Acute Coronary Syndromes Revascularization is the restoration of blood supply to ischemic myocardium in an effort to limit ongoing damage, reduce ventricular irritability, and improve short-term and long-term outcomes. (msdmanuals.com)
Outcomes5
  • In a recent report on outcomes after thrombolysis for ALLI, end-stage renal disease and poor pedal outflow were predictors for limb loss after multi-variable testing, whereas diabetes mellitus (DM) and the Rutherford Classification were not [ 2 ]. (springer.com)
  • This paper describes a cooperative model that uses the skills already present in a DGH to deliver a thrombolysis service initiated in the emergency department by the emergency physicians, and describes the outcomes of that service in comparison with the SITS-MOST trial. (bmj.com)
  • The aim of this paper is to describe the service and to describe outcomes for stroke thrombolysis in a DGH setting. (bmj.com)
  • Background Door-to-needle time (DTN) has an important impact on thrombolysis and reperfusion outcomes in the treatment of acute ischaemic stroke. (bmj.com)
  • Thrombolysis has been shown to improve stroke outcomes by reducing disability, 1 and it is most effective when administered early. (bmj.com)
Plasmin4
  • Fibrin-bound plasminogen will be converted by thrombolytic drugs to plasmin, the rate-limiting step in thrombolysis. (medscape.com)
  • The thrombolytic agents available today are serine proteases that work by converting plasminogen to the natural fibrinolytic agent plasmin. (medscape.com)
  • The ability of these substances to catalyze the conversion of plasminogen to plasmin is affected only slightly by the presence or absence of local fibrin clot. (medscape.com)
  • After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. (lookformedical.com)
Rescue percutaneous coronary int1
Thrombectomy1
  • Techniques of EVT included stent retriever thrombectomy, stent retriever-assisted continuous aspiration, direct contact aspiration, and multimodal techniques including a rescue balloon mounted coronary stent placement. (bmj.com)
Intra-arterial thrombolysis5
  • The aim of this study was to evaluate the outcome of local intra-arterial thrombolysis for ALLI in patients with diabetes mellitus (DM). (springer.com)
  • Patients with DM presenting with ALLI differ in clinical characteristics, presentation, and aetiology compared to patients with DM, and have a higher rate of major amputation and lower amputation-free survival rate after intra-arterial thrombolysis. (springer.com)
  • Local intra-arterial thrombolysis is the preferred treatment option for acute lower limb ischaemia (ALLI) in many vascular centres. (springer.com)
  • Patients undergoing intra-arterial thrombolysis between 2001 and 2010 have been reported previously with a follow up until January 17, 2012 [ 5 ]. (springer.com)
  • It may also be used directly into the affected blood vessel during an angiogram (intra-arterial thrombolysis), e.g. when patients present with stroke beyond three hours or in severe deep vein thrombosis (catheter-directed thrombolysis). (wikimili.com)
Catheter-Directed Thrombolysis2
  • Catheter-directed thrombolysis involves the acceleration of the body's natural thrombolytic pathway. (medscape.com)
  • The lower circulating drug levels are the suggested mechanism for the lower incidence of systemic and, in particular, intracranial hemorrhagic complications reported with catheter-directed thrombolysis. (medscape.com)
Fibrinolysis2
  • Large trials have shown that mortality can be reduced using thrombolysis (particularly fibrinolysis ) in treating heart attacks . (wikimili.com)
  • In countries with more extensive and independent qualifications, prehospital thrombolysis ( fibrinolysis ) may be initiated by the emergency care practitioner (ECP). (wikimili.com)
Percutaneous Coronary Interventions2
  • Bivalirudin in Percutaneous Coronary Interventions and Acute Coronary Syndromes: New Concepts, New Directions. (baiminstitute.org)
  • We also are interested in how components of the blood clotting and fibrinolytic systems contribute to the pathogenesis of chronic vascular disorders, such as atherosclerosis and restenosis after percutaneous coronary interventions. (missouri.edu)
Stroke thrombolysis3
  • Background Stroke thrombolysis is strongly supported as an effective therapy for selected cases of early stroke. (bmj.com)
  • Data at Scarborough DGH were compared with data from the SITS-MOST European-wide study of stroke thrombolysis. (bmj.com)
  • Conclusion Stroke thrombolysis can be effectively delivered in a non-specialist (a non-hyper-acute stroke centre) DGH in the UK. (bmj.com)
Platelet5
  • Platelet activation and aggregation plays an integral role in the pathogenesis of acute coronary syndrome (ACS). (jabfm.org)
  • Three rescue therapies were used after failed thrombolysis: percutaneous coronary intervention (74%), retreatment with thrombolysis (39%) and platelet glycoprotein (GP) IIb/IIIa receptor blockers (53%), often in combination. (eur.nl)
  • Bleeding was related to heparin usage and platelet GP IIb/IIIa receptor blockers, as was the insertion of catheters for percutaneous coronary intervention or intra-aortic balloon pumps. (eur.nl)
  • Cigarette smoking may increase the thrombus burden in patients with acute coronary syndrome (ACS).Thrombosis results largely from platelet aggregation and fibrin formation due to rupture or ulceration of the atheroma. (researchsquare.com)
  • The platelet-to-lymphocyte ratio (PLR) has been used as a systemic inflammatory biomarker to predict the prognosis of neoplasms, coronary disease, autoimmune disease and stroke [ 23 , 24 , 33 , 36 ]. (the-jcen.org)
Reperfusion2
CABG2
  • Surgeons use CABG to treat people who have severe coronary heart disease (CHD). (cdc.gov)
  • During CABG, a healthy artery or vein from the body is connected, or grafted, to the blocked coronary artery. (cdc.gov)
STEMI1
Thrombi1
  • It should be kept in mind that the thrombolysis process works best on recently formed thrombi. (medscape.com)
Revascularization1
  • Use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing coronary revascularization. (baiminstitute.org)
Circulation1
Oral anticoagulant therapy1
  • Heparin therapy and oral anticoagulant therapy must always follow a course of thrombolysis. (medscape.com)
Cardiac3
  • Patients with a confirmed acute coronary syndrome should be admitted to a cardiac care unit or high dependency unit with continuous ECG rhythm monitoring. (bmj.com)
  • Patients who have had ischaemic ECG changes, or cardiac troponin release or raised CK-MB enzyme demonstrated at any time during admission, have a confirmed acute coronary syndrome. (bmj.com)
  • A Heart Team approach (involving interventional cardiologists and cardiac surgeons) should be used in patients with diabetes and multivessel coronary artery disease and in patients with severe left main disease and a high Syntax score. (medscape.com)
PPCI1
Blood vessels1
  • Thrombolysis, also called fibrinolytic therapy , is the breakdown ( lysis ) of blood clots formed in blood vessels , using medication. (wikimili.com)
Thrombus burden1
  • Smoking may increase the thrombus burden in patients with acute coronary syndrome. (researchsquare.com)
Thrombolytic agents1
  • Thrombolysis medication errors: benefits of bolus thrombolytic agents. (tci-thaijo.org)
Clopidogrel1
  • Medications at the time of admission included clopidogrel 75 mg daily for coronary artery stenosis. (surgicalneurologyint.com)
Heparin2
Outcome2
  • Several factors have been associated with improved or adverse outcome in terms of amputation-free survival in ALLI patients undergoing thrombolysis. (springer.com)
  • for clinical presentation, aetiology, results of thrombolysis, and outcome has not been addressed sufficiently. (springer.com)
Systemic1
  • For the treatment of a massive pulmonary embolism , catheter-directed therapy is a safer and more effective alternative to systemic thrombolysis. (wikimili.com)
Clots1
Therapy2
  • Of patients treated with thrombolysis and not referred from other hospitals (n=154) 36% received rescue therapy for failed thrombolysis. (eur.nl)
  • Rescue therapy is a widely used strategy for failed thrombolysis, but is associated with a high bleeding rate. (eur.nl)
Ischaemic stroke1
  • Thrombolysis reduces major disability or death when given within 3 hours (or perhaps even 6 hours) of ischaemic stroke onset when there are no contraindications to treatment. (wikimili.com)